Openbookopenbook
Equity
CRMD
+0.0 · +0.00%
USD · NASDAQ

CorMedix Inc(CRMD) Stock Analysis | Healthcare

USD --+0.00%
Reward69High
Risk45Moderate
75%Data
Strong 40% profit margin · Revenue growing 157% YoY
Quality Compounder
Market Cap:639.14M
ⓘ
Reward Rating
69
High
Reward Assessment
75% data coverage
Top 25% of stocksView factors
ⓘ
Risk Rating
45
Moderate
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CRMD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for CRMD, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $15.40.

What is CorMedix Inc?

, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

CRMD · Verdict

Solid reward · moderate risk

CRMD stands out on profitability and valuation, but watch the volatility signal.

Based on 88% data coverage

CRMD · Verdict

What’s working & what to watch

Strengths 4

  • Profitability96/100

    52% net margin · 55% ROE

  • Valuation85/100

    P/E 15.2×

  • Balance sheet80/100

    Interest covered 54.9×

  • Cash flow75/100

    55% free-cash-flow margin

Watchouts 1

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is CorMedix Inc?

, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 639.14M, and a P/E ratio of 3.8x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (69)

The scoring profile indicates moderate reward potential, with profitability and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

CBIOSmall Cap / 637M market cap
Crescent Biopharma, Inc.
Compare
AUTLSmall Cap / 641M market cap
Autolus Therapeutics Ltd
Compare
SVASmall Cap / 642M market cap
Sinovac Biotech Ltd
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap639.14M
P/E Ratio3.7615
Dividend YieldN/A
Beta1.496
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
390,000 shares
$1.1M
0
9-12months
5163,997 shares
$2.2M
125,000 shares
$276k
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.